News AZ's Alexion extends gMG options with two Klygefa approvals AstraZeneca's Alexion unit has won approval in the US and EU for Klygefa, billed as a future blockbuster, for generalised myasthenia gravis (gMG).
News Windward Bio catches $175m from its IPO Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.
News AZ boosts vaccine capabilities with Omniose buy AstraZeneca has bought a US biotech developing polysaccharide conjugate vaccines for bacterial infections, Omniose, after a three-year partnership.
News Hutchmed, AZ file Orpathys for lung cancer on ESMO data Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.
News AZ seeking $1.5bn in annual savings by end-2029 AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
News ESMO26: AZ's claudin ADC doubles survival in GI cancers AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.